Analyst David Dai from UBS maintained a Buy rating on Moderna and keeping the price target at $40.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Dai has given his Buy rating due to a combination of factors that highlight Moderna’s strategic initiatives and financial outlook. The company is focusing on disciplined financial management, which is expected to support its path to achieving cash breakeven by 2028. This includes anticipated topline growth of up to 10% in 2026, driven by strategic partnerships and cost reductions.
Additionally, Moderna’s revenue growth is projected to be bolstered by the expansion of its respiratory vaccine portfolio, including new vaccine launches for flu and norovirus between 2026 and 2028. Furthermore, the oncology franchise is seen as a key long-term growth driver, with significant developments expected from the pivotal Phase 3 trial for Intismeran in adjuvant melanoma. These strategic moves are anticipated to enhance investor sentiment and position Moderna for future success.
In another report released on November 7, Piper Sandler also maintained a Buy rating on the stock with a $69.00 price target.